Kiemeney Lambertus

Kiemeney Lambertus is a Professor of Cancer Epidemiology at the Department of Health Evidence, Radboud University Medical Center in Nijmegen, Netherlands. He serves as Chair of the Department of Health Evidence and Scientific Director of the Radboud Institute for Health Sciences. His academic career includes roles as Head of the Department of Cancer Registry and Research, and Director of Research at the Netherlands Comprehensive Cancer Organisation. Lambertus holds a Master's in Biomedical Sciences (cum laude) from Radboud University and a Bachelor's in Physiotherapy (cum laude).

His research focuses on urological cancers, genetic and clinical epidemiology, and biobanking. Key areas include prostate and bladder cancer genetics, risk prediction models, and validation of biomarkers like PCA3. He has pioneered studies on FGFR3 and JAG1 genes in bladder cancer susceptibility, and demonstrated the safety of coal tar treatments in dermatology.

His over 500 publications include foundational work in genome-wide association studies (GWAS), with a Nature Genetics paper on bladder cancer susceptibility genes cited over 200 times. Lambertus has received global recognition including the Dominique Chopin Distinguished Researcher Award and inclusion in Thomson Reuters' most influential scientists list.

• Teaching Excellence: Multiple lecturer-of-the-year awards highlight his educational contributions.
• Leadership: Oversee large research institutes and national cancer initiatives.
• Global Impact: Collaborates with institutions worldwide, including Johns Hopkins University and the European Institute of Oncology.

Current research emphasizes translational studies linking genetic discoveries to clinical outcomes, with a focus on reducing overdiagnosis in prostate cancer screening.